stockrowAssembly Biosciences, Inc.
ASMB Healthcare Biotechnology
Assembly Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72.3 million, up 153.5% from fiscal 2024.
- Revenue
- +38.9%
- EPS
- +85.0%
- Free cash flow
- +7.58%
Quarter to June 2026, against a year earlier
Follow ASMB
Alert me
Assembly Biosciences, Inc. (ASMB) EV/Sales
As of 3 November 2026, Assembly Biosciences, Inc. (ASMB) trades at a EV/Sales of 0.8×. Over the past ten years it has ranged from −1.9× (July 2024) to 113× (March 2018); the current reading is higher than 64% of that period. That is below the Biotechnology industry median of 9.5× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 4.6× | — |
| FY2024 | −0.6× | — |
| FY2023 | −1.0× | — |
| FY2021 | −0.6× | — |
| FY2020 | 0.0× | — |
| FY2019 | 16.5× | (18.01%) |
| FY2018 | 20.1× | (74.15%) |
| FY2017 | 77.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.6× | (22.50%) |
| Mar 2026 | 3.4× | (25.29%) |
| Dec 2025 | 4.6× | 84.05% |
| Sep 2025 | 2.5× | 29.30% |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AVTX Avalo Therapeutics, Inc. compare | −57.2× |
| BLSM BlossomHill Therapeutics, Inc. compare | n/m |
| RLMD Relmada Therapeutics, Inc. compare | n/m |
| ZURA Zura Bio Limited compare | n/m |
| ASMB Assembly Biosciences, Inc. | 0.8× |
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | 2.2× |
| EDIT Editas Medicine, Inc. compare | 2.8× |
| CCCC C4 Therapeutics, Inc. compare | 5.2× |
| ALT Altimmune, Inc. compare | 1,889× |
| Biotechnology industry median | 9.5× |
| Healthcare sector median | 3.5× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)